Sales: The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

Dexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.

Q4 2024 Earnings Call Transcript February 13, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported ...

Much progress has been made in diabetes technology over the past decade. Continuous glucose monitoring has achieved high accuracy and reliability, resulting ...

Discover how smartphones with advanced sensors are revolutionizing health monitoring. Explore ECG, SpO2 tracking, ...

JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 ...